Quick reference
- When to use
- Use F12.20 when the client meets criteria for Cannabis Use Disorder, Moderate. Determine severity by symptom count: mild (2-3), moderate (4-5), severe (6+). Specify current status: in early remission, in sustained remission, or on maintenance therapy.
- Duration
- Early remission: 3-12 months without criteria met (except craving). Sustained remission: 12+ months. On maintenance therapy: receiving agonist medication. Tolerance/withdrawal don't count if on prescribed medication.
- Session codes
- Pair with CPT 90834/90837 for therapy. SBIRT: 99408/99409. Medication management: 99213/99214. Group therapy: 90853. Use 96127 for AUDIT/DAST screening. MAT visits may use specific E/M codes.
- Key indicators
- Impaired control over substance use • Social impairment • Risky use • Pharmacological indicators (tolerance, withdrawal) • Craving • Continued use despite problems • Giving up activities
What F12.20 represents
Cannabis Use Disorder at the moderate level indicates significant problems related to marijuana use, with 4-5 criteria met. Despite legalization trends, cannabis can cause clinically significant impairment.
Key diagnostic criteria
Same 11-criteria framework as other substance use disorders applied to cannabis use, with 4-5 criteria met. Cannabis withdrawal is now recognized in DSM-5.
Documentation essentials
Document pattern of use, specific criteria met, functional impact, and any withdrawal symptoms.
Differential diagnosis
Rule out other substance use, anxiety disorders (cannabis may mask or worsen), and psychotic disorders (cannabis-associated psychosis).
Treatment planning
Motivational enhancement therapy, CBT, contingency management. No FDA-approved medications currently.
Insurance & billing
Accepted code. Document functional impairment related to cannabis use.
Updates & changes
DSM-5 added cannabis withdrawal syndrome and removed legal problems criterion.
Documentation pitfalls
Don't dismiss cannabis use disorder due to legalization status. Document clinical significance.
References
- American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.).